A pair of late-stage trials conducted by Eli Lilly found that their experimental once-weekly insulin can effectively lower blood sugar levels, comparable to daily insulins currently in use. This announcement by the drugmaker on Thursday has intensified the competition with Novo Nordisk in the development of longer-acting insulins, showcasing the ongoing race for innovation in diabetes treatment. The results highlight the potential of Eli Lilly’s new insulin therapy to offer a convenient and effective option for managing diabetes.
Source link
Could Labour introduce a 2% wealth tax?
The proposed 2% wealth tax on individuals with assets over £10 million is gaining attention ahead of the government's Spring Statement, with support from Labour MPs, Green Party, lobby groups, and charity organizations. The tax could potentially raise £24 billion per year, but critics are skeptical due to possible tax avoidance strategies. While many support the tax to fund public services and address economic inequality, challenges in administration and potential negative impacts on wealth accumulation...
Read more